A carregar...
Cryptococcal meningoencephalitis in an IgG(2)-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report
BACKGROUND: Fingolimod (Gilenya®), a first-in-class sphingosine-1-phosphate receptor modulator is approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod-induced selective immunosuppression leads to an increased risk of opportunistic infections such as cryptococcosis. So far...
Na minha lista:
| Publicado no: | BMC Neurol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7187502/ https://ncbi.nlm.nih.gov/pubmed/32340606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-020-01741-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|